Spectrum and degree of CDK drug interactions predicts clinical performance

Molecular Cancer Therapeutics

Volumn 15, Issue 10, 2016, Pages 2273-2281

  Chen, Ping ^a   Lee, Nathan V ^a   Hu, Wenyue ^a   Xu, Meirong ^a   Ferre, Rose Ann ^a   Lam, Hieu ^a   Bergqvist, Simon ^a   Solowiej, James ^a   Diehl, Wade ^a   He, You Ai ^a   Yu, Xiu ^a   Nagata, Asako ^a   Vanarsdale, Todd ^a   Murray, Brion W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABEMACICLIB; AG 024322; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLIN T1; DINACICLIB; PALBOCICLIB; RETINOBLASTOMA PROTEIN; RIBOCICLIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; CYTOTOXICITY; DRUG BINDING; DRUG EXPOSURE; DRUG INTERACTION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME CONFORMATION; HINGE REGION; HUMAN; HUMAN CELL; LIGAND BINDING; LIPOPHILICITY; MOLECULAR INTERACTION; NEWBORN; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; CELL SURVIVAL; CHEMISTRY; CLUSTER ANALYSIS; CONFORMATION; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIUM CELL; METABOLISM; MOLECULAR MODEL; MONONUCLEAR CELL; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; CYCLIN-DEPENDENT KINASES; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RATS;

EID: 84990948149     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0300     Document Type: Article

References (53)

1. Schwartz PA, Murray BW. Protein kinase biochemistry and drug discovery. Bioorg Chem 2011;39:192-210.
2. Talluri S, Dick FA. Regulation of transcription and chromatin structure by pRB: here, there and everywhere. Cell Cycle 2012;11:3189-98.
3. Santo L, Siu KT, Raje N. Targeting cyclin-dependent kinases and cell cycle progression in human cancers. Semin Oncol 2015;42:788-800.
4. Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov 2016;6:353-67.
5. Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res 2014;16:207.
6. Zhu L. Tumour suppressor retinoblastoma protein Rb: a transcriptional regulator. Eur J Cancer 2005;41:2415-27.
7. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130-46.
8. Sanchez-Martinez C, Gelbert LM, Lallena MJ, De Dios A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorg Med Chem Lett 2015;25:3420-35.
9. O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 2016;13:417-30.
10. Criscitiello C, Viale G, Esposito A, Curigliano G. Dinaciclib for the treatment of breast cancer. Expert Opin Investig Drugs 2014;23:1305-12.
11. Nemunaitis JJ, Small KA, Kirschmeier P, Zhang D, Zhu Y, Jou YM, et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclindependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 2013;11:259.
12. Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer 2014;14:169-76.
13. Brown AP, Courtney CL, Criswell KA, Holliman CL, Evering W, Jessen BA. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion. Cancer Chemother Pharmacol 2008;62:1091-101.
14. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, et al. RBpathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2010;9:4153-63.
15. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010;29:4018-32.
16. Cadoo KA, Gucalp A, Traina TA. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer 2014;6:123-33.
17. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-76.
18. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011;104:1862-8.
19. Vidula N, Rugo HS. Cyclin-Dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data. Clin Breast Cancer 2016;16:8-17.
20. Murphy CG, Dickler MN. The role of CDK4/6 inhibition in breast cancer. Oncologist 2015;20:483-90.
21. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
22. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20:3379-83.
23. Migliaccio I, Di Leo A, Malorni L. Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol 2014;26:568-75.
24. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35.
25. Laurenti E, Frelin C, Xie S, Ferrari R, Dunant CF, Zandi S, et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 2015;16:302-13.
26. Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 2015;125:90-101.
27. Morschhauser F, Bouabdallah K, Stilgenbauer S, Thieblemont C, Wolf M, De Guibert S, et al. Clinical activity of abemaciclib (LY2835219), a cell cycle inhibitor selective for CDK4 and CDK6, in patients with relapsed or refractory mantle cell lymphoma. Blood 2014;125:3067.
28. Vidula N, Rugo HS. Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data. Clin Breast Cancer 2016;16:8-17.
29. Dukelow T, Kishan D, Khasraw M, Murphy CG. CDK4/6 inhibitors in breast cancer. Anti-cancer Drugs 2015;26:797-806.
30. Murray BW, Miller N. Durability of kinase-directed therapies-a network perspective on response and resistance. Mol Cancer Ther 2015;14:1975-84.
31. Copeland RA. Evaluation of enzyme inhibitors in drug discovery. Hoboken, NJ: John Wiley & Sons, Inc.; 2005.
32. Morrison JF. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 1969;185:269-86.
33. Murphy DJ. Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design. Anal Biochem 2004;327:61-7.
34. Perrin D, Fremaux C, Shutes A. Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery. Expert Opin Drug Discov 2010;5:51-63.
35. Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol Crystallogr 2011;67:293-302.
36. Honda R, Lowe ED, Dubinina E, Skamnaki V, Cook A, Brown NR, et al. The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles. EMBO J 2005;24:452-63.
37. Smart OS, Womack TO, Flensburg C, Keller P, Paciorek W, Sharff A, et al. Exploiting structure similarity in refinement: automated NCS and targetstructure restraints in BUSTER. Acta Crystallogr D Biol Crystallogr 2012;68:368-80.
38. Cho YS, Borland M, Brain C, Chen CH, Cheng H, Chopra R, et al. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6. J Med Chem 2010;53:7938-57.
39. Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. eLife. 2014:e02872.
40. Rubin SM. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci 2013;38:12-9.
41. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9:2344-53.
42. Cheng AC, Eksterowicz J, Geuns-Meyer S, Sun Y. Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index. J Med Chem 2010;53:4502-10.
43. McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS. Molecular conformations, interactions, and properties associatedwith drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci U S A 2012;109:18281-9.
44. Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, Zhang J, et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol 2011;18:699-710.
45. Tarcsay A, Keseru GM. Contributions of molecular properties to drug promiscuity. J Med Chem 2013;56:1789-95.
46. Zhang C, Lopez MS, Dar AC, Ladow E, Finkbeiner S, Yun CH, et al. Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology. ACS Chem Biol 2013;8:1931-8.
47. Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U. Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer. ACS Chem Biol 2015;10:2680-6.
48. Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 2014;32:825-37.
49. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005;48:2388-406.
50. Garriga J, Grana X. CDK9 inhibition strategy defines distinct sets of target genes. BMC Res Notes 2014;7:301.
51. Ye X, Zhu C, Harper JW. A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. Proc Natl Acad Sci U S A 2001;98:1682-6.
52. Malumbres M. Cyclin-dependent kinases. Genome Biol 2014;15:122.
53. Lu H, Schulze-Gahmen U. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. J Med Chem 2006;49:3826-31.